IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy

Journal of Immunology

Volumn 162, Issue 4, 1999, Pages 2399-2405

  Luo, Yi ^a   Chen, Xiaohong ^a   Downs, Tracy M ^a   DeWolf, William C ^a   O'Donnell, Michael A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Israel Deaconess Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; INTRAVESICAL DRUG ADMINISTRATION; MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; CELLS, CULTURED; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INTERFERON ALFA-2B; INTERFERON TYPE II; TACHYPHYLAXIS; TH1 CELLS; URINARY BLADDER NEOPLASMS;

EID: 0033557730     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Parker, S. L., T. Tong, S. Bolden, and P. A. Wingo. 1996. Cancer statistics, 1996. CA-Cancer J. Clin. 46:5.
2. Kavoussi, L. R., R. J. Torrence, D. P. Gillen, M. A. Hudson, E. O. Haaff, S. M. Dresner, T. L. Ratliff, and W. J. Catalona. 1988. Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J. Urol. 139:935.
3. Dejager, R., P. Guinan, and D. Lamm. 1991. Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin. Urollogy 38:507.
4. Herr, H. W., C. M. Pinsky, and W. F. Whitmore. 1986. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J. Urol. 135:265.
5. Lamm, D. L. 1992. Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am. 19:573.
6. Steg, A., S. Adjiman, and B. Debre. 1992. BCG therapy in superficial bladder tumours: complications and precautions. Eur. Urol. 21 (Suppl. 2):35.
7. Lamm, D. L., A. D. P. M. Van Der Meijden, A. Morales, S. A. Brosman, W. J. Catalona, H. W. Herr, M. S. Soloway, A. Steg, and F. M. J. Debruyne. 1992. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J. Urol. 147:596.
8. Torti, F. M., L. D. Shortliffe, R. D. Williams, W. C. Pitts, R. L. Kempson, J. C. Ross, J. Palmer, F. Meyers, M. Ferrari, J. Hannigan, et al. 1988. α-Interferon in superficial bladder cancer: a Northern California Oncology Group study. J. Clin. Oncol. 6:476.
9. Glashan, R. W. 1990. A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder. J. Urol. 144:658.
10. Williams, R. D. 1988. Intravesical interferon a in the treatment of superficial bladder cancer. Semin. Oncol. 15:10.
11. Chodak, G. 1989. Intravesical interferon treatment of superficial bladder cancer. Urology 34:84.
12. Bercovich, E., M. Deriu, F. Manferrari, and G. Irianni. 1995. BCG vs. BCG plus recombinant α-interferon 2b in superficial tumors of the bladder. Arch. Ital. Urol. Androl. 67:257.
13. Stricker, P., K. Pryor, T. Nicholson, D. Goldstein, D. Golovsky, R. Ferguson, P. Nash, S. Ehsman, J. Rumma, G. Mammen, and R. Penny. 1996. Bacillus Calmette-Guérin plus intravesical interferon α-2b in patients with superficial bladder cancer. Urology 48:957.
14. Sarosdy, M. F., and C. A. Kierum. 1989. Combination immunotherapy of murine transitional cell cancer using BCG and an interferon-inducing pyrimidinone. J. Urol. 142:1376.
15. Riggs, D. R., W. F. Tarry, J. I. DeHaven, J. Sosnowski, and D. L. Lamm. 1992. Immunotherapy of murine transitional cell carcinoma of the bladder using α and γ interferon in combination with other forms of immunotherapy. J. Urol. 147: 212.
16. Ratliff, T. L. 1992. Role of the immune response in BCG for bladder cancer. Eur. Urol. 21 (Suppl. 2):17.
17. Ratliff, T. L., D. P. Gillen, and W. J. Catalona. 1987. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137: 155.
18. Ralliff, T. L., J. K. Ritchey, J. J. J. Yuan, G. L. Andriole, and W. J. Catalona. 1993. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150:1018.
19. Peuchmaur, M. G. Benoit. A. Viellefond, A. Chevalier, G. Lemaigre, E. D. Martin, and A. Jardin. 1989. Analysis of mucosal bladder leukocyte sub-populations in patients treated with intravesical bacillus Calmelte-Guérin. Urol. Res. 17.299.
20. Kelley, D. R., E. O. Haaff, M. Becich, J. Lage, W. C. Bauer, S. M. Dresner, W. J. Catalona, and T. L. Ratliff. 1986. Prognostic value of PPD skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J. Urol. 135:268.
21. Prescott, S., K. James, T. B. Hargreave, G. D. Chisholm, and J. F. Smyth. 1992. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol. 147:1636.
22. de Reijke, T. M., E. C. de Boer, K. H. Kurth, and D. H. Schamhart. 1996. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. 155:477.
23. Bohle, A., C. Nowe, A. J. Ulmer, J. Musehold, J. Gerdes, A. G. Hofstetter, and H. D. Flad. 1990. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J. Urol. 144:59.
24. Jackson, A.M., A.B. Alexandroff, R.W. Kelly, A. Skibinska, K. Esuvaranathan, S. Prescott, G.D. Chisholm, and K. James. 1995. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guérin (BCG) immunotherapy. Clin. Exp. Immunol. 99:369.
25. O'Donnell, M. A., X. Chen, and W. C. DeWolf. 1996. Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules. J. Urol. 155:1030A.
26. Esuvaranathan, K., A. B. Alexandroff, M. McIntyre, A. M. Jackson, S. Prescott G. D. Chisholm, and K. James. 1995. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J. Urol. 154:572.
27. Zlotta, A. R., A. Drowart, K. Huygen, J. De Bruyn, H. Shekarsarai, M. Decock, M. Pirson, F. Jurion, K. Palfliet, O. Denis, et al. 1997. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin. Exp. Immunol. 109:157.
28. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc. R. Soc. London Ser. B. 147:258.
29. Baron, S., S. K. Tyring, W. R. Fleischmann Jr., D. H. Coppenhaver, D. W. Niesel, G. R. Klimpel, G. J. Stanton, and T. K. Hughes. 1991. The interferons: mechanisms of action and clinical applications. JAMA 266:1375.
30. Pestka, S., J. A. Langer, K. C. Zoon, and C. E. Samuel. 1987. Interferons and their actions. Annu. Rev. Biochem. 56:727.
31. + T cells. J. Exp. Med. 178:1655.
32. Parronchi, P., M. De Carli, R. Manetti, C. Simonelli, S. Sampognaro, M. Piccinni, D. Macchia, E. Maggi, G. del Prete, and S. Romagnani. 1992. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 149:2977.
33. Brinkmann, V., C. H. Heusser, J. Baer, E. Kilchherr, and F. Erard. 1992. Interferon α suppresses the capacity of T cells to help antibody production by human B cells. J. Interferon Res. 12:267.
34. Wenner, C. A., M. L. Guler, S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1996. Roles of IFN-γ and IFN-α in IL-12-induced T helper cell-1 development. J. Immunol. 156:1442.
35. Downs, T. M., A. Szilvasi, and M. A. O'Donnell. 1997. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-α 2B. J. Urol. 158:1.
36. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, et al. 1991. New use of BCG for recombinant vaccines. Nature 351:456.
37. Ralliff, T. L., and W. J. Catalona. 1989. Depressed proliferative responses in patients treated with 12 weeks of intravesical BCG. J. Urol. 141:230A (abstr.).
38. Keeley, J., F.X., E. Lattime, P. McCue, and L. G. Gomella. 1994. A comparison of the local immune response to intravesical α-interferon and bacillus Calmette-Guérin (BCG) in patients with superficial bladder cancer. J. Urol. 151:473A (abstr.).
39. De Boer, E. C., W. H. De Jong, P. A. Steerenberg, L. A. Aarden, E. Tetteroo, E. R. De Groot, A. P. Van der Meijden, P. D. Vegt, F. M. Dehruyne, and E. J. Ruitenberg. 1992. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol. Immunother. 34:306.
40. Pryor, K., P. Stricker, P. Russell, D. Golovsky, and R. Penny. 1995. Antiproliferative effects of bacillus Calmette-Guérin and Interferon α2b on human bladder cancer cells in vitro. Cancer Immunol. Immunother. 41:309.
41. Borden, E. C., D. S. Groveman, T. Nasu, C. Renzikoff, and G. T. Bryan. 1984. Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro. J. Urol. 132:800.
42. Tzai, T.-S., and S.-N. Lin. 1992. Interferon-α can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes. J. Urol. 147:523.
43. Trotta, P. 1985. Interferon α 2: summary of pre-clinical data. Dev. Oncol. 27:13.
44. Fearon, D. T. and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50.
45. Sieling, P. A., J. S. Abrams, M. Yamamura, P. Salgame, B. R. Bloom, T. H. Rea, and R. L. Modlin. 1993. Immunosuppressive roles for IL-10 and IL-4 in human infection: in vitro modulation of T cell responses in leprosy. J. Immunol. 150: 5501.
46. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon γ or inlerleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59.
47. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081.
48. Trinchieri, G. 1995. Interleukin-12: a proinflammalory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
49. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Scherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
50. Chan, S. H., B. Perussia, J. W. Gupta, M. M. P. Kobayashi, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869.
51. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
52. + T cells to enhance priming for imerferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90:10188.
53. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88.
54. Ushio, S., M. Namba, T. Okura, K. Hatorri, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii. et al. 1996. Cloning of the cDNA for human IFN-γ inducing factor, expression in Escherichia coli and studies on the biological activities of the protein. J. Immunol. 156:4274.
55. Sander, B., U. Skansen-Saphir, O. Damm, L. Hakansson, J. Andersson, and U. Andersson. 1995. Sequential production of Th1 and Th2 cytokines in response to live bacillus Calmette-Guérin. Immunology 86:512.
56. Downs, T. M., X. Chen, W. C. DeWolf, and M. A. O'Donnell. 1997. Urinary cytokine expression following intravesical BCG treatment and its correlation with patient symptoms. Proc. 66th Annu. Meet. N. Engl. Sect. Am. Urol. Assn. 66:118.
57. Fujimoto, T., R. B. Duda, A. Szilvasi, X. Chen, M. Mai, and M. A. O'Donnell. 1997. Streptococcal preparation OK-432 is a potent inducer of interleukin-12 and a Th1 dominant state. J. Immunol. 158:5619.
58. Belldegrun, A. S., J. R. Franklin, M A. O'Donnell, L. G. Gomella, E. Klein, R. Neri, U. O. Nseyo, T. L. Ratliff, and R. D. Williams. 1998. Superficial bladder cancer: the role of interferon α. J. Urol. 159:1793.